Zymeworks Insider Spotlight: Catalysts Ahead News ad

Zymeworks (NYSE: ZYME) came into the spotlight in late December when major shareholder EcoR1 Capital increased its stake. EcoR1, already a 10% shareholder and board member, made several purchases in December and in the early days of 2025, bringing its stake to more than 15 million shares. This is a significant increase and confirms the outlook, including multiple catalysts in 2025. These include the recent approval of a flagship oncology drug, pending additional approvals, and the development of a robust and promising pipeline. What is Zymeworks? It is a clinical-stage biopharmaceutical company working on new treatments for hard-to-treat cancers and other diseases.

The true insiders, the company executives, own a small percentage of the company, but this is offset by strong ownership by the sellers. Institutions, including large shareholders such as EcoR1 Capital, own more than 90% of the shares and are not selling them. As for EcoR1, it is a small investment company specializing in innovative treatments for a wide range of diseases.

Analysts are also backing the stock as coverage, sentiment and price target rise. Coverage more than doubled in 2024, resulting in a strong Moderate Buy and a price target above $19. The $19 target suggests 35% upside by year-end, and revisions suggest higher prices are likely. The most recent targets were released late in the year as the news cycle improved and pointed to a mid-$20 range. Skeptics include companies like Wells Fargo, which believes the stock is already factored into 2025 catalysts and predicts it will decline.

Zymeworks Lead Treatment Receives Initial Approval

The main catalyst for Zymeworks’ share price is Zichera’s endorsement. The FDA granted accelerated and limited approval for patients with biliary tract cancer with limited or no alternatives. The approval is now effective and is expected to lead to subsequent approvals for additional treatments and uses in other countries. Zanidatamab, a drug from Zichera, is currently in 10 Phase III studies for further approval in the US and worldwide.

However, the critical details are the expected milestone payments. These milestones are subject to FDA approval and will net the company more than $500 million. This money is critical to the pipeline’s progress and will provide sufficient capital to maintain operations in the second half of 2027. Otherwise, the company may be forced to raise capital through other means, reducing shareholder value.

Although well capitalized, revenue and earnings prospects will be a headwind for this market. Analysts are forecasting sluggish revenue over the next four to six quarters, which will consist entirely of milestone payments received as the project progresses. The planned activity in 2025 includes the expected results of Phase III for Zichera as an initial measure, which will be an important catalyst for the share price in the event of a positive result. Other catalysts include the introduction of new candidate endorsements and the expected expansion of the candidate pool.

Short sellers could limit Zymeworks stock’s gains

Short-term interest in Zymeworks was not prohibitively high in early January, but was high enough to cause concern. That 6% figure rises with the share price and could cap growth this year. Price action in early January is showing signs of resistance at a critical level, so there is cause for concern. The critical level is around $16.50, which corresponds to market consolidations in 2019 and 2022, which provide targets for strong resistance. Failure to rise above $16.50 will leave the market range-bound and likely to move lower by the end of the year.

Critical support lies near a group of moving averages, including the short-term 30-day EMA, long-term 150-day EMA and ultra-long-term two-year EMA, which show a golden crossover. A golden crossover indicates a change in market sentiment, which often results in higher stock prices.

Companies in this article:

Experience

Thomas Hughes has been a writer for InsiderTrades.com since 2019.

Areas of Specialization

Technical analysis, S&P 500; retail, consumer, consumer staples, dividends, high yield, small cap, technology, economic data, oil, cryptocurrencies

Education

Associate in Culinary Technology

Past experience

Market watcher, trader and investor of numerous websites. Founded Passive Market Intelligence LLC to provide market research analytics.